Alteration of bioelectrically-controlled processes in the embryo: A teratogenic mechanism for anticonvulsants

Reproductive Toxicology

Volumn 47, Issue , 2014, Pages 111-114

  Hernández Díaz, Sonia ^a   Levin, Michael ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Anticonvulsants; Developmental biology; Neurotransmission; Structural malformations

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FOLIC ACID; GLYCINE RECEPTOR; HISTONE DEACETYLASE; LAMOTRIGINE; MOOD STABILIZER; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; REACTIVE OXYGEN METABOLITE; SEROTONIN RECEPTOR; TOPIRAMATE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE; ETHOSUXIMIDE; GABAPENTIN; PREGABALIN; ZONISAMIDE; TERATOGENIC AGENT;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL DIVISION; CLEFT PALATE; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; EMBRYO DEVELOPMENT; EPILEPSY; FETUS RISK; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; HEART SEPTUM DEFECT; HUMAN; HYPOSPADIAS; LIMB DEFECT; NERVE POTENTIAL; NEURAL TUBE DEFECT; NEUROTRANSMISSION; OXIDATIVE STRESS; PREGNANCY; PREVALENCE; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; SEIZURE; TERATOGENICITY; UROGENITAL TRACT DISEASE; ACTION POTENTIAL; BIOENERGY; ELECTRIC POTENTIAL; PRENATAL EXPOSURE; RISK FACTOR; ABNORMALITIES, DRUG-INDUCED; DRUG EFFECTS; FEMALE; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; EMBRYONIC DEVELOPMENT; EPILEPSY; FEMALE; HUMANS; PREGNANCY; SYNAPTIC TRANSMISSION; TERATOGENS;

EID: 84905017841     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.04.008     Document Type: Article

References (76)

1. Holmes L.B., Harvey E.A., Coull B.A., Huntington K.B., Khoshbin S., Hayes A.M., et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001, 344:1132-1138.
2. Matalon S., Schechtman S., Goldzweig G., Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002, 16:9-17.
3. Wyszynski D., Nambisan M., Surve T., Alsdorf R., Smith C., Holmes L. Antiepileptic drug pregnancy registry: increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:956-961.
4. Hernandez-Diaz S., Smith C.R., Shen A., Mittendorf R., Hauser W.A., Yerby M., et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012, 78:1692-1699.
5. Nelson K., Holmes L.B. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 1989, 320:19-23.
6. Peller A., Westgate M.-N., Holmes L. Trends in congenital malformations, 1974-1999: effect of prenatal diagnosis and elective termination. Obstet Gynecol 2004, 104:957-964.
7. Omtzigt J., Los F., Grobbee D., Pijpers L., Jahoda M., Brandenburg H., et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992, 42:119-125.
8. Morrow J., Russell A., Guthrie B., Parsons L., Robertson I., Waddell R., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
9. Diav-Citrin O., Shechtman S., Bar-Oz B., Cantrell D., Arnon J., Ornoy A. Pregnancy outcome after in utero exposure to valproate evidence of dose relationship in teratogenic effect. CNS Drugs 2008, 22:325-334.
10. Wide K., Winbladh B., Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr Scand 2004, 93:174-176.
11. Arpino C., Brescianini S., Robert E., Castilla E., Cocchi G., Cornel M., et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000, 41:1436-1446.
12. Jentink J., Loane M., Dolk H., Barisic I., Garne E., Morris J., et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
13. Nakane Y., Okuma T., Takahashi R., Sato Y., Wada T., Sato T., et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980, 21:663-680.
14. Czeizel A.E., Bod M., Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol 1992, 8:122-127.
15. Dansky L.V., Rosenblatt D.S., Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992, 42:32-42.
16. Jentink J., Dolk H., Loane M., Morris J., Wellesley D., Garne E., et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and casecontrol study. Br Med J 2010, 341.
17. Kallen B.A. Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994, 8:203-205.
18. Sabers A., Dam M., a-Rogvi-Hansen B., Boas J., Sidenius P., Laue Friis M., et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004, 109:9-13.
19. Vajda F., Hitchcock A., Graham J., O'Brien T., Lander C., Eadie M. The Australian register of antiepileptic drugs in pregnancy: the first 1002 pregnancies. Austr N Z J Obstet Gynaecol 2007, 47:468-474.
20. Cunnington M., Ferber S., Quartey G. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007, 48:1207-1210. the International Lamotrigine Pregnancy Registry Scientific Advisory Committee.
21. Holmes L.B., Baldwin E., Habecker E., Glassman L., Wong S., Wyszynsky D.F. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008, 70:2152-2158.
22. Hunt S., Russell A., Smithson W., Parsons L., Robertson I., Waddell R., et al. Topiramate in pregnancy, preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008, 71:272-276.
23. Molgaard-Nielsen D., Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011, 305:1996-2002.
24. Margulis A.V., Mitchell A.A., Gilboa S.M., Werler M.M., Mittleman M.A., Glynn R.J., et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012, 207:405 e1-4057e.
25. Shapiro S., Hartz S.C., Siskind V., Mitchell A.A., Slone D., Rosemberg L., et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976, 1:272-275.
26. Gadoth N., Millo Y., Taube E., Bechar M. Epilepsy among parents of children with cleft lip and palate. Brain Dev 1987, 9:296-299.
27. Finnell R.H., Bielec B., Nau H. Anticonvulsant drugs: mechanisms and pathogenesis of teratogenicity. Drug toxicity in embryonic development 1997, vol. II:121-159. Springer, Berlin.
28. Dansky L.V., Finnell R.H. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: human studies. Reprod Toxicol 1991, 5:301-335.
29. Fried S., Kozer E., Nulman I., Einarson T.R., Koren G. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004, 27:197-202.
30. Werler M.M., Ahrens K.A., Bosco J.L., Mitchell A.A., Anderka M.T., Gilboa S.M., et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 2011, 21:842-850.
31. Kaneko S., Battino D., Andermann E., Wada K., Kan R., Takeda A., et al. Congenital malformations due to anti-epileptic drugs. Epilepsy Res 1999, 33:145-158.
32. Bromfield E., Dworetsky B., Wyszynski D., Smith C., Baldwin E., Holmes L. Valproate teratogenicity and epilepsy syndrome. Epilepsia 2008, 49:2122-2124.
33. Butterworth C., Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989, 50:353-358.
34. Ogawa Y., Kaneko S., Otani K., Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991, 8:75-78.
35. Hernandez-Diaz S., Werler M.M., Walker A.M., Mitchell A.A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000, 343:1608-1614.
36. Buehler B.A., Delimont D., Van Waes M., Finnell R.H. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990, 322:1567-1572.
37. Lindhout D. Pharmacogenetics and drug interactions: role in antiepileptic-drug-induced teratogenesis. Neurology 1992, 42:43-47.
38. Na L., Wartenberg M., Nau H., Hescheler J., Sauer H. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth defects research Part A. Clin Mol Teratol 2003, 67:174-180.
39. Wu G., Nan C., Rollo J.C., Huang X., Tian J. Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J Biomed Sci 2010, 17:16.
40. Levin M. Molecular bioelectricity in developmental biology: new tools and recent discoveries: control of cell behavior and pattern formation by transmembrane potential gradients. Bioessays 2012, 34:205-217.
41. Levin M. Bioelectric mechanisms in regeneration: unique aspects and future perspectives. Semin Cell Dev Biol 2009, 20:543-556.
42. McCaig C.D., Song B., Rajnicek A.M. Electrical dimensions in cell science. J Cell Sci 2009, 122:4267-4276.
43. Blackiston D.J., McLaughlin K.A., Levin M. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle 2009, 8:3519-3528.
44. Burg E.D., Remillard C.V., Yuan J.X. K+ channels in apoptosis. J Membr Biol 2006, 209:3-20.
45. Rajnicek A.M., Foubister L.E., McCaig C.D. Growth cone steering by a physiological electric field requires dynamic microtubules, microfilaments and Rac-mediated filopodial asymmetry. J Cell Sci 2006, 119:1736-1745.
46. McCaig C.D., Rajnicek A.M., Song B., Zhao M. Controlling cell behavior electrically: current views and future potential. Physiol Rev 2005, 85:943-978.
47. Hinard V., Belin D., Konig S., Bader C.R., Bernheim L. Initiation of human myoblast differentiation via dephosphorylation of Kir2.1 K+ channels at tyrosine 242. Development 2008, 135:859-867.
48. 2+ signals to human myoblast differentiation and fusion. Development 2006, 133:3107-3114.
49. Konig S., Hinard V., Arnaudeau S., Holzer N., Potter G., Bader C.R., et al. Membrane hyperpolarization triggers myogenin and myocyte enhancer factor-2 expression during human myoblast differentiation. J Biol Chem 2004, 279:28187-28196.
50. Vandenberg L.N., Morrie R.D., Adams D.S. V-ATPase-dependent ectodermal voltage and pH regionalization are required for craniofacial morphogenesis. Dev Dyn 2011, 240:1889-1904.
51. Tristani-Firouzi M., Etheridge S.P. Kir 2.1 channelopathies: the Andersen-Tawil syndrome. Pflugers Arch 2010, 460:289-294.
52. Adams D.S., Robinson K.R., Fukumoto T., Yuan S., Albertson R.C., Yelick P., et al. Early, H+-V-ATPase-dependent proton flux is necessary for consistent left-right patterning of non-mammalian vertebrates. Development 2006, 133:1657-1671.
53. Levin M., Thorlin T., Robinson K.R., Nogi T., Mercola M. Asymmetries in H+/K+-ATPase and cell membrane potentials comprise a very early step in left-right patterning. Cell 2002, 111:77-89.
54. Aw S., Koster J., Pearson W., Nichols C., Shi N.Q., Carneiro K., et al. The ATP-sensitive K(+)-channel (K(ATP)) controls early left-right patterning in Xenopus and chick embryos. Dev Biol 2010, 346:39-53.
55. Blackiston D., Adams D.S., Lemire J.M., Lobikin M., Levin M. Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway. Dis Model Mech 2011, 4:67-85.
56. Ding Y., Brackenbury W.J., Onganer P.U., Montano X., Porter L.M., Bates L.F., et al. Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity. J Cell Physiol 2008, 215:77-81.
57. Brackenbury W.J., Djamgoz M.B., Isom L.L. An emerging role for voltage-gated Na+ channels in cellular migration: regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist 2008, 14:571-583.
58. Fraser S.P., Diss J.K., Chioni A.M., Mycielska M.E., Pan H., Yamaci R.F., et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 2005, 11:5381-5389.
59. Pai V.P., Aw S., Shomrat T., Lemire J.M., Levin M. Transmembrane voltage potential controls embryonic eye patterning in Xenopus laevis. Development 2012, 139:313-323.
60. Fein A.J., Wright M.A., Slat E.A., Ribera A.B., Isom L.L. scn1bb, a zebrafish ortholog of SCN1B expressed in excitable and nonexcitable cells, affects motor neuron axon morphology and touch sensitivity. J Neurosci 2008, 28:12510-12522.
61. Pineda R.H., Svoboda K.R., Wright M.A., Taylor A.D., Novak A.E., Gamse J.T., et al. Knockdown of Nav1.6a Na+ channels affects zebrafish motoneuron development. Development 2006, 133:3827-3836.
62. Levin M. Endogenous bioelectric signals as morphogenetic controls of development, regeneration, and neoplasm. The physiology of bioelectricity in development, tissue regeneration, and cancer 2011, 39-89. CRC Press, Boca Raton, FL. C.E. Pullar (Ed.).
63. Beane W.S., Morokuma J., Adams D.S., Levin M. A chemical genetics approach reveals H,K-ATPase-mediated membrane voltage is required for planarian head regeneration. Chem Biol 2011, 18:77-89.
64. Chen E.H., Olson E.N. Unveiling the mechanisms of cell-cell fusion. Science 2005, 308:269-373.
65. Buznikov G.A., Schmukler Y.B. Possible role of prenervous neurotransmitters in cellular interactions of early embryogenesis: a hypothesis Neurochemical. Research 1981, 6:55-68.
66. Lange C., Prenninger S., Knuckles P., Taylor V., Levin M., Calegari F. The H(+) vacuolar ATPase maintains neural stem cells in the developing mouse cortex. Stem Cells Dev 2011, 20:843-850.
67. Sundelacruz S., Levin M., Kaplan D.L. Membrane potential controls adipogenic and osteogenic differentiation of mesenchymal stem cells. PLoS ONE 2008, 3:e3737.
68. Yasuda T., Adams D.J. Physiological roles of ion channels in adult neural stem cells and their progeny. J Neurochem 2010, 114:946-959.
69. Root C.M., Velazquez-Ulloa N.A., Monsalve G.C., Minakova E., Spitzer N.C. Embryonically expressed GABA and glutamate drive electrical activity regulating neurotransmitter specification. J Neurosci 2008, 28:4777-4784.
70. Andang M., Hjerling-Leffler J., Moliner A., Lundgren T.K., Castelo-Branco G., Nanou E., et al. Histone H2AX-dependent GABA(A) receptor regulation of stem cell proliferation. Nature 2008, 451:460-464.
71. Deisseroth K., Malenka R.C.G.A.B.A. excitation in the adult brain: a mechanism for excitation-neurogenesis coupling. Neuron 2005, 47:775-777.
72. Deisseroth K., Singla S., Toda H., Monje M., Palmer T.D., Malenka R.C. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. Neuron 2004, 42:535-552.
73. Fukumoto T., Blakely R., Levin M. Serotonin transporter function is an early step in left-right patterning in chick and frog embryos. Dev Neurosci 2005, 27:349-363.
74. Fukumoto T., Kema I.P., Levin M. Serotonin signaling is a very early step in patterning of the left-right axis in chick and frog embryos. Curr Biol 2005, 15:794-803.
75. Carneiro K., Donnet C., Rejtar T., Karger B.L., Barisone G.A., Diaz E., et al. Histone Deacetylase activity is necessary for left-right patterning during vertebrate development. BMC Dev Biol 2011, 11:29.
76. Vajda F., Lander C., O'Brien T., Hitchcock A., Graham J., Solinas C., et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia 2004, 45:1466.